New stroke drug candidate passes early safety check in healthy volunteers
NCT ID NCT07083362
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called HRS-8829 in 83 healthy adults aged 18 to 55. The study used a placebo-controlled, dose-escalation design to see how the body handles the drug and to check for side effects. The goal was to gather safety and drug-level information before testing in stroke patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIA STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
Conditions
Explore the condition pages connected to this study.